Natalie Staplin
Overview
Explore the profile of Natalie Staplin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
7640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu D, Judge P, Staplin N, Haynes R, Herrington W
Nephrol Dial Transplant
. 2025 Feb;
40(Supplement_1):i70-i79.
PMID: 39907541
Abstract: Nephrology has benefited from conducting increasingly large high-quality trials in the last 5-10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple...
2.
De La Sierra A, Ruilope L, Staplin N, Stergiou G, Williams B
J Hypertens
. 2025 Jan;
43(4):642-648.
PMID: 39791439
Objective: We aimed to evaluate the risks of death and cardiovascular death of different subtypes of masked hypertension, defined by either isolated daytime or nighttime blood pressure (BP) elevation, or...
3.
Judge P, Tuttle K, Staplin N, Hauske S, Zhu D, Sardell R, et al.
Nephrol Dial Transplant
. 2024 Nov;
PMID: 39533115
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium...
4.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
5.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Nephrol Dial Transplant
. 2024 Sep;
PMID: 39277784
Background And Hypothesis: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout...
6.
Vale C, Godolphin P, Fisher D, Horby P, Kosiborod M, Hochman J, et al.
Lancet Diabetes Endocrinol
. 2024 Sep;
12(10):735-747.
PMID: 39250923
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects. Published evidence from randomised...
7.
De La Sierra A, Ruilope L, Staplin N, Gorostidi M, Vinyoles E, Segura J, et al.
Hypertension
. 2024 Sep;
81(11):2350-2356.
PMID: 39247961
Background: Resistant hypertension is characterized by elevated blood pressure (BP) despite using 3 antihypertensive agents. Ambulatory BP monitoring (ABPM) detects the presence of white-coat resistant hypertension (24-hour BP <130/80 mm ...
8.
Staplin N
Nephrol Dial Transplant
. 2024 Sep;
39(Supplement_2):ii1-ii2.
PMID: 39235194
No abstract available.
9.
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol
. 2024 Jul;
12(8):545-557.
PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...
10.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Clin J Am Soc Nephrol
. 2024 Jul;
PMID: 38949880
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy...